Inhibrx Biosciences, Inc.INBXNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank78
3Y CAGR+3.3%
5Y CAGR+27.8%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+3.3%/yr
vs +46.0%/yr prior
5Y CAGR
+27.8%/yr
Recent deceleration
Acceleration
-42.7pp
Decelerating
Percentile
P78
Within normal range
vs 5Y Ago
3.4x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $23.29M | -81.8% |
| 2024 | $127.91M | +335.3% |
| 2023 | $29.38M | +39.1% |
| 2022 | $21.12M | +71.0% |
| 2021 | $12.36M | +80.7% |
| 2020 | $6.84M | -24.2% |
| 2019 | $9.02M | +93.8% |
| 2018 | $4.65M | +78.4% |
| 2017 | $2.61M | +66.4% |
| 2016 | $1.57M | - |